Txcell SA, of Valbonne, France, signed a strategic agreement appointing Lentigen Technology Inc. (LTI), of Gaithersburg, Md., a wholly owned subsidiary of Miltenyi Biotec GmbH, as its contract manufacturing organization (CMO) for the GMP production of its HLA A2 CAR lentiviral vector, which will be used to manufacture Txcell's CAR regulatory T cells targeting transplant rejection.